Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT07097363)

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma: a one-minute explainerNCT070973631 min

Biospecimen Collection trial for B-Cell Non-Hodgkin Lymphoma (NCT07097363). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated, high-risk aggressive B-cell lymphoma who are candidates for six cycles of dose-adjusted EPOCH-R. One urgent treatment cycle can be allowed before entry.

The idea: add injected epcoritamab to EPOCH-R chemotherapy and rituximab. Epcoritamab connects CD3-bearing T cells with CD20-bearing lymphoma cells to direct an immune attack. Researchers assess safety and tumor response over six 21-day cycles.

This phase 2 study plans 18 patients. Mengyang Di leads at Fred Hutchinson and the University of Washington in Seattle, the sole recruiting US site. Active central-nervous-system lymphoma is excluded.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.